When possible, we offer our patients the option to participate in clinical trials. Clinical trials allow cutting edge treatment options to be tested by the people they were designed to help.
Clinical Trials
Offering Cutting Edge Treatments
Trials Open to Enrollment
If you are interested in any of these open opportunities, we encourage you to call our office or talk with your provider to explore your options.
Protocol AU-011-301: September 2023 -Present:
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma
Sponsor: Aura Biosciences, Inc.
ClinicalTrials.gov identifier: NCT06007690
Status: Open to Enrollment
Protocol AL: November 2023 -present:
A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy (Protocol AL)
Sponsor: Jaeb Center for Health Research (JCHR)
ClinicalTrials.gov identifier: NCT05844982
Status: Open to Enrollment
UBX1325-04: September 2023-present:
A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients with Diabetic Macular Edema
Sponsor: UNITY Biotechnology, Inc.
ClinicalTrials.gov identifier: NCT06011798
Status: Open to Enrollment
Trials In Follow-Up
Feel free to contact our office with any questions about these opportunities currently in the follow-up stage.
Protocol ALXN2040-GA-201: November 2022-present:
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Sponsor: Alexion Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT05019521
Status: Closed to Enrollment
Protocol OPT-302-1005: April 2021-present:
A Phase 3, Multicenter, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
Sponsor: Opthea
ClinicalTrials.gov identifier: NCT04757636
Status: Closed to Enrollment
Study Protocol ISIS 696844-CS5: March 2021-present:
A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-Lrx, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Sponsor: Ionis Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03815825
Status: Closed to Enrollment
Completed Studies
Our team would love to talk more with you about these completed studies and what other opportunities are available.
202 Study Protocol AU-011-202: August 2020 – present:
A Phase 2 trial of AU-011 via suprachoroidal administration with a dose escalation phase (open-label, ascending single and repeat dose) and a randomized, masked dose expansion phase designed to evaluate the safety and efficacy of AU-011 in subjects with primary indeterminate lesions and small choroidal melanoma.
Sponsor: Aura Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT04417530
Status: Closed
Study Protocol KS301P103: July 2021-present:
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)
Sponsor: Kodiak Sciences, Inc.
ClinicalTrials.gov Identifier: NCT04592419
Status: Closed
Protocol GR41987: July 2021-present:
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema
Sponsor: F. Hoffman-La Roche Ltd
ClinicalTrials.gov Identifier: NCT04432831
Status: Closed
Study Protocol UBX1325-02: July 2021-present:
A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema
Sponsor: UNITY Biotechnology, Inc.
ClinicalTrials.gov Identifier: NCT04857996
Status: Closed
Learn More About Clinical Trials
If you are interested in learning more about any of these opportunities or next steps, please contact our office.